These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2376111)

  • 1. Influence of infusion method on serum tobramycin concentrations in adults with cystic fibrosis.
    Pleasants RA; Williams DM; Waltner WE; Knowles MR
    Clin Pharm; 1990 Jul; 9(7):541-5. PubMed ID: 2376111
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of cystic fibrosis--step by step.
    Hazinski TA
    J Pediatr; 2001 Oct; 139(4):3A. PubMed ID: 11598588
    [No Abstract]   [Full Text] [Related]  

  • 4. Breast-feeding in a woman with cystic fibrosis undergoing antibiotic intravenous treatment.
    Festini F; Ciuti R; Taccetti G; Repetto T; Campana S; De Martino M
    J Matern Fetal Neonatal Med; 2006 Jun; 19(6):375-6. PubMed ID: 16801316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin.
    Elidemir O; Maciejewski SR; Oermann CM
    Pediatr Pulmonol; 2000 Jan; 29(1):43-5. PubMed ID: 10613786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobramycin dosage recommendation in patients with cystic fibrosis.
    Davis RL; Mendelman P; Ramsey B; Smith AL
    Infection; 1989; 17(1):41. PubMed ID: 2921090
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of serum aminoglycoside concentrations produced by two infusion methods.
    Bosch DE; Williams DN
    Clin Pharm; 1990 Oct; 9(10):777-80. PubMed ID: 2242658
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of four intravenous infusion methods on tobramycin pharmacokinetics.
    Pleasants RA; Sawyer WT; Williams DM; McKenna WR; Powell JR
    Clin Pharm; 1988 May; 7(5):374-9. PubMed ID: 3383543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of intravenous meropenem and tobramycin versus ceftazidime and tobramycin in cystic fibrosis.
    Latzin P; Fehling M; Bauernfeind A; Reinhardt D; Kappler M; Griese M
    J Cyst Fibros; 2008 Mar; 7(2):142-6. PubMed ID: 17766190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Bakker W
    Ther Drug Monit; 1993 Feb; 15(1):52-9. PubMed ID: 8451782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling.
    Jones A; Beisty J; McKenna D; Clough D; Webb K; Morris J; Keevil B
    Eur Respir J; 2012 Jun; 39(6):1537-8. PubMed ID: 22654009
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Gappa M; Steinkamp G; Tümmler B; von der Hardt H
    Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of clinical pharmacokinetic services provided to children and adolescents with cystic fibrosis.
    Kearns GL; Jiménez JF; Brown AL; Warren RH
    J Ark Med Soc; 1985 Oct; 82(5):215-9. PubMed ID: 2933385
    [No Abstract]   [Full Text] [Related]  

  • 17. Dosage of tobramycin in cystic fibrosis--a short report.
    Chrystyn H; Alexander JM
    J Clin Hosp Pharm; 1985 Jun; 10(2):219-20. PubMed ID: 4019795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of tobramycin delivery by four i.v. infusion methods.
    Pleasants RA; Sawyer WT; Williams DM; McKenna WR; Brown JM; Powell JR
    Clin Pharm; 1988 May; 7(5):367-73. PubMed ID: 3383542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.